Previous 10 | Next 10 |
Sorrento Therapeutics (SRNE) files for 996,803 share common stock offering by Selling Shareholder.See below company's ownership structure: For further details see: Sorrento holder to offer 997K shares
Sorrento Therapeutics ([[SRNE]] +7.4%) perks up, albeit on below-average volume, in reaction to its announcement that it has discovered a small molecule named Salicyn-30 that, it says, produced a 3-4 log (1,000x - 10,000x) reduction in SARS-CoV-2 viral load in a cell model.It identified Salic...
In preclinical studies, Salicyn-30, a small molecule, demonstrated potent in-vitro viral load reduction of 3-4 log in SARS-CoV-2 infection model in normal healthy VERO E6 cells. Salicyn-30 displays a novel mechanism of inhibition of SARS-CoV-2, with potential additive benefits whe...
Shares of the clinical-stage biotech Sorrento Therapeutics (NASDAQ: SRNE) gained a whopping 46.1% during the month of September, according to data provided by S&P Global Market Intelligence . For comparison, the iShares Nasdaq Biotechnology ETF gained only 1.8% last mont...
Scilex Holding, a majority-owned subsidiary of Sorrento Therapeutics (SRNE) announces Q/Q sales growth in ZTlido.Scilex expects Q3 2020 ZTlido net sales to grow 26% to ~$7.2M, compared to $5.7M in Q2-2020. Scilex’s SP-102 (SEMDEXA) is currently being evaluated in Phase 3 clinical ...
Preliminary Q3 2020 net sales of ZTlido ® of approximately $7.2 million, quarter-over-quarter growth of 26% compared to $5.7MM in Q2-2020 despite the continued impact of COVID-19 pandemic. The Phase 3 pivotal trial investigating SP-102 non-opioid therapy for lumbosacral radic...
Sorrento Therapeutics (SRNE) will host a R&D Day conference call and webcast on October 13, 2020 focusing on its multi-modal approach to COVID-19. Management will highlight strategic advancement, challenges, key pipeline updates and drivers of future growth in the COVID-19 space.R&D D...
SAN DIEGO, Oct. 04, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced it will host a R&D Day conference call and simultaneous webcast on October 13 th , 2020 focusing on its comprehensive multi-modal approach to COVID-19. ...
Zosano Pharma (ZSAN) -53% after FDA discipline review letter for Qtrypta.Selecta Biosciences (SELB) -44% after SEL-212 misses primary endpoint in mid-stage gout study.LogicBio Therapeutics (LOGC) -26% on launch of equity offering.ChinaNet Online Holdings (CNET) -...
At the beginning of this year, Sorrento Therapeutics (NASDAQ: SRNE) was focused on its pain management drug, resiniferatoxin, as well as its Dimeric Antigen Receptor-T (DAR-T) cell therapy targeting various blood cancers and solid tumors. But the biotech has made a major piv...
News, Short Squeeze, Breakout and More Instantly...
Sorrento Therapeutics Inc. Company Name:
SRNE Stock Symbol:
NASDAQ Market:
Sorrento Therapeutics Inc. Website:
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...